Acetylation Phenotype in Colorectal Carcinoma

Cancer Research

Volumn 47, Issue 5, 1987, Pages 1466-1469

  Ilett, Kenneth F ^a   Kwa, Rose ^a   Detchon, Peter ^b   Castleden, William M ^b   David, Beverley M ^c,d  

^a Departments of Pharmacology ^*

^b Department of Surgery ^*

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d CURTIN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

N4 ACETYLSULFADIMIDINE; SULFADIMIDINE;

ACETYLATION; CLINICAL ARTICLE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DIAGNOSIS; HUMAN; LARGE INTESTINE; PHENOTYPE; PRIORITY JOURNAL;

ACETYLATION; ADENOCARCINOMA; ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BIOTRANSFORMATION; COLONIC NEOPLASMS; FEMALE; HUMANS; KIDNEY; MALE; MIDDLE AGED; PHENOTYPE; RECTAL NEOPLASMS; SULFAMETHAZINE;

EID: 0023096984     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Clark, D. W. J. Genetically determined variability in acetylation and oxidation. Drugs, 29: 342-375, 1985.
2. Weber, W. W. and Hein, D. W. A-acetylation pharmacogenetics. Pharmacol. Rev., 37: 25–79, 1985.
3. Drayer, D. E., and Reidenberg, M. M. Clinical consequences of polymorphic acetylation of basic drugs. Clin. Pharmacol. Ther., 22: 251-258, 1977.
4. Uetrecht, J. P., and Woosley, R. L. Acetylator phenotype and lupus erythematosus. Clin. Pharmacokinet., 6:118-134, 1981.
5. Hanngren, A., Borga, O., and Sjoqvist, F. Inactivation of isoniazid (INH) in Swedish tuberculosis patients before and during treatment with para-amino-salicylic acid (PAS). Scand. J. Respir. Dis., 51:61-69, 1970.
6. Manila, M. J., and Tiitinen, H. The rate of isoniazid inactivation in Finnish diabetic and non-diabetic patients. Ann. Exp. Med. Biol. (Fenn.), 45: 423–427, 1967.
7. McLaren, E. H., Burden, A. C., and Moorhead, P. J. Acetylator phenotype in diabetic neuropathy. Br. Med. J., 2:291-293, 1977.
8. Burrows, A. W., Hockaday, T. D. R., Mann, J. I., and Taylor, J. G. Diabetic polymorphism according to acetylator status. Br. Med. J., 1:208-210, 1978.
9. Shenfield, G. M., McCann, V. J., and Tjokrosetio, R. Acetylator status in diabetic neuropathy. Diabetologia, 22:441-444, 1982.
10. Cartwright, R. A., Glashan, R. W., Rogers, H. J., Ahmad, R. A., Hall, D. B., Higgins, E., and Kahn, M. A. The role of 7V-acetyItransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet, 2:842-846, 1982.
11. Wolf, H., Lower, G. M. Jr., and Bryan, G. T. Role of jY-acetyltransferase phenotype in human susceptibility to bladder carcinogenic arylamines. Scand. J. Urol. Nephrol., 14: 161–165, 1980.
12. Evans, D. A. P., Eze, L. C., and Whibley, E. J. The association of slow acetylator phenotype with bladder cancer. J. Med. Genet., 20: 330–333, 1983.
13. Butovskaya, L. N., Krupkin, R. G., Bochina, T. A., Shikpova, A. A., and Pavlova, M. V. Acetylator phenotype in patients with breast cancer. Oncology (Basel), 35:185-188, 1978.
14. Cartwright, R. A. Epidemiological studies of N-acetylation and C-centre ring oxidation in neoplasia. In: G. S. Omenn and H. V. Gelboin (eds.), Banbury Report No. 16: Genetic Variability in Responses to Chemical Exposure, pp. 359–368. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1984.
15. Schut, H. A., and Castonguay, A. Metabolism of carcinogenic amino derivatives in various species and DNA alkylation by their metabolites. Drug. Metab. Rev., 15:753-839, 1984.
16. Hatton, W. M., and Clarke-Hundley, M. D. (eds.). The Western Australian Cancer Registry. Cancer in Western Australia 1983, p. 53. Perth: Health Department of Western Australia, 1985.
17. Lee, E. J. D., and Lee, L. K. H. A simple pharmacokinetic method for separating the three acetylation phenotypes: a preliminary report. Br. J. Clin. Pharmacol., 13:375-378, 1982.
18. Schroeder, H. Simplified method for determining acetylator phenotype. Br. Med. J., 3:506-507, 1972.
19. Metzler, C. M. A users manual for NONLIN. Technical report 2792/69/ 7292/005. Kalamazoo, MI: The Upjohn Company, 1969.
20. DuSouich, P., McLean, A. J., Stoeckel, K., Ohlendorf, D., and Gibaldi, M. Screening methods using sulfamethazine acetylation phenotypes. Clin. Pharmacol. Ther., 26: 757–765, 1979.
21. Chapron, D. J., Kramer, P. A., and Mercik, S. A. Kinetic discrimination of three sulfamethazine acetylation phenotypes. Clin. Pharmacol. Ther., 27: 104-113, 1980.
22. Gachalyi, B., Vas, A., Hajos, P., and Kaldor, A. Acetylator phenotypes: effect of age. Eur. J. Clin. Pharmacol., 26:43-45, 1984.
23. Pontiroli, A. E., DePasqua, A., Bonisolli, L., and Pozza, A. Ageing and acetylator phenotype as determined by administration of sulphadimidine. Eur. J. Clin. Pharmacol., 28:485-486, 1985.
24. Farah, F., Taylor, W., Rawlins, M. D., and James, O. Hepatic drug acetylation and oxidation: effects of ageing in man. Br. Med. J., 2: 155–156, 1977.
25. Bruce, W. R., Varghese, A. J., Furrer, R., and Land, P. C. A mutagen in the feces of normal humans. In: H. H. Hiat, J. P. Watson and J. A. Winsten (eds.), Origins of Human Cancer, pp. 1641–1646. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1977.
26. Ehrich, M., Aswell, J. E., Van Tassell, R. L., and Wilkins, T. D. Mutagens in the faeces of 3 South African populations at risk for colon cancer. Mutat. Res., 64: 231–240, 1979.
27. Djuric, Z., Fifer, E. K., and Beland, F. A. Acetyl coenzyme A-dependent binding of carcinogenic and mutagenic dinitropyrenes to DNA. Carcinogenesis (Lond.), 6:941-944, 1985.
28. McQueen, C. A., Maslansky, C. J., and Williams, G. M. Role of acetylation polymorphism in determining susceptibility of cultured rabbit hepatocytes to DNA damage by aromatic amines. Cancer Res., 43:3120-3123, 1983.
29. McQueen, C. A., Maslansky, C. J., Glowinski, I. B., Crescenzi, S. B. Weber, W. W., and Williams, G. M. Relationship between the genetically determined acetylator phenotype and DNA damage induced by hydralazine and 2-aminofluorene in cultured rabbit hepatocytes. Proc. Natl. Acad. Sci. USA, 79: 1269–1272, 1982.